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Abstract
Introduction: As mortality and morbidity after a curative resection remains high, it is essential to identify
pre-operative factors associated with an early death after a major resection.
Methods: Between 1998 and 2008, we selected a population of 331 patients having undergone a major
hepatectomy including segment I with a lymphadenectomy and a common bile duct resection for a
proven hilar cholangiocarcinoma in 21 tertiary centres. The study’s objective was to identify pre-operative
predictors of early death (<12 months) after a resection.
Results: The study cohort consisted of 221 men and 110 women, with a median age of 61 years (range:
24–85). The post-operative mortality and morbidity rates were 8.2% and 61%, respectively. The 1-, 3- and
5-year overall survival rates were 85%, 64% and 53%, respectively. The median tumour size was 23 mm
on pathology, ranging from 8 to 40. A tumour size >30 mm [odds ratio (OR) 2.471 (95% confidence interval
(CI) 1.136–7.339), P = 0.001] and major post-operative complication [OR 3.369 (95% CI 1.038–10.938),
P = 0.004] were independently associated with death <12 months in a multivariate analysis.
Conclusion: The present analysis of a series of 331 patients with hilar cholangiocarcinoma showed that
tumour size >30 mm was independently associated with death <12 months.
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Introduction
Hilar cholangiocarcinoma is challenging in terms of staging and
surgical treatment.1,2 The central location of the tumour in the
liver and its close relationship with vascular structures have
resulted in a low resectability rate and high morbidity and mor-
tality.3 However, it has long been accepted that a complete surgical
resection is the only way to provide patients with a chance of a
cure or long-term survival.1,2 Indeed, many surgeons have adopted
an aggressive approach combining resection of the main biliary
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confluence with an extended hepatectomy including the caudate
lobe and lymphadenectomy.4–9 This radical treatment is respon-
sible for post-operative mortality and morbidity rates of up to
10–13% and 75%, respectively.5 In spite of a 5-year survival rate in
the range of 25–30% being reported for patients who’s resection
was considered R0,3,4 the high risk of local tumour recurrence is
still not satisfactory. In these settings, the utility of surgery with
high mortality and morbidity rates can legitimately be ques-
tioned, particularly in patients with a dismal prognosis.
Hence, the present study sought to identify pre-operative
factors associated with early death (i.e. within 12 months of resec-
tion) after a major liver resection for hilar cholangiocarcinoma in
a nationwide registry of operated patients (the AFC-HC study
group).
Patients and methods
Patient sourcing and selection
The HC-AFC-2009 study group was created under the auspices
of the French Association of Surgery (AFC) in 2008 in order to
generate a retrospective registry (after comprehensive pathology
database screening) of all consecutive patients with hilar
cholangiocarcinoma undergoing surgery between January 1998
and January 2008. The protocol was approved by the AFC’s
investigational review board. Of 710 patients considered for
curative treatment, 595 (84%) had undergone a resection. We
selected patients having undergone a major hepatectomy (right
or left hepatectomy, right or left trisectionectomy and anterior
hepatectomy) including segment I with lymphadenectomy and
common bile duct resection for proven hilar cholangiocar-
cinoma. Patients who underwent a resection for intra-hepatic
cholangiocarcinoma with secondary hilar extension9 were
excluded as well as patients treated with neoadjuvant therapy.
Patients undergoing adjacent organ, arterial, a minor resection or
a liver resection without segment I were excluded owing to the
high rate of R1 resections (51% and 52%, respectively). Three
patients having undergone a hilar en bloc resection of extrahe-
patic bile ducts with the portal vein bifurcation were also not
selected. The final selected population comprised 331 patients
from 21 surgical centres located throughout France. The flow-
chart is detailed in Fig. 1.
Study criteria
Peri-operative management and surgical strategy have evolved
over the past 3 decades in the 21 centres. Portal vein embolization
was mainly considered for patients with compromised liver func-
tion when the anticipated future remnant volume is <40% of the
total liver volume. Pre-operative imaging was used to determine
the extent of the tumour precisely and to assess surgical
resectability. Pre-operative diagnostic images used included inter
alia computed tomography (CT). Since 2003 multidetector row
computed tomography (MDCT) and more recently magnetic
resonance cholangiography have replaced CT in most centres.
Imaging characteristics included tumour location, biliary exten-
sion with growth pattern (infiltrative and intraductal, papillary),
parenchyma atrophy, portal vein and hepatic artery invasion and
lymph node enlargement. Lesions were classified and validated
Patients operated for hilar
cholangiocarcinoma N = 710
Non-resectable disease N = 115
Isolated common bile duct resection N = 68
Intrahepatic cholangiocarcinoma N = 44
Neoadjuvant therapy N = 4
Minor or atypical resection N = 45
Adjacent organ or arterial resection N = 31
No segment I resection N = 10
No lymphadenectomy N = 59
En bloc hilar resection N = 3
Curative-intent resection N = 595
Liver resection N = 527
Selected patients N = 331
Figure 1 Flowchart
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according to both Bismuth–Corlette classification and DeOliveira
staging.10,11
In brief, the extrahepatic bile duct of the resected specimen was
opened longitudinally from the distal resection margin up to the
proximal margin, to accurately evaluate the ductal margin status.
All surgical specimen slides were not available for review;
however, a copy of the histology report on the tumour specimen
was requested for each patient.12 All pathology reports were
reviewed by an independent pathologist (D.C.). There was no
standardized protocol for pathological analysis of specimens
within all 21 tertiary hospitals. A R0 resection was defined as the
presence of a macroscopically and microscopically tumour-free
resection margin. A R1 resection was defined as microscopic evi-
dence of tumour tissue at the resection margin including biliary,
liver parenchyma and adjacent fat tissue. Histological findings
were described using the TNM Classification of Malignant Tumors
(7th edition, 2009) by the International Union Against Cancer.
Post-operative complications were stratified according to the
Clavien–Dindo classification,13 which defines major complica-
tions by a score of 3 or more. Specific liver complications were
detailed as follows: liver failure defined according to the ‘50–50
criteria’ on post-operative day 5;14 ascites defined as an abdominal
drainage output of more than 10 ml per kg per day after the third
post-operative day; and biliary leakage defined by a bilirubin con-
centration in the drainage fluid of more than threefold higher
than that in serum.15 Both complications and operative mortality
were considered as those occurring within 90 days of surgery, or at
any time during the post-operative hospital stay.
Study design
The study’s objective was to identify pre-operative predictors of
early death, i.e. within 12 months of resection whatever the reason
(died of the disease, no evidence of disease, missing data etc). All
patients surviving the operation were monitored and the
follow-up was updated at the end of 2010. The median follow-up
was 42 months (range, 6–235). Variables of interest were system-
atically double-checked by three surgeons (J.M.R., O.F. and D.F.)
and marked as missing as appropriate. Discrepancies in the
reported data were corrected after communication between the
statistician/data manager and the study centre in question.
Statistical analysis
Data are reported as the prevalence, mean (standard deviation) or
median (range). Continuous data were compared by means of the
Mann–Whitney U-test and ordinal data were compared in a χ2
test or Fisher’s exact test, as appropriate. Tests for independent
samples were applied. Statistical analysis was performed using
SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA). Predic-
tive factors for early death were determined by uni- and multi-
variate analysis. For the univariate analysis, the significance level
of each factor was tested alone. For the multivariate analysis, a
backward-elimination approach in a multiple logistic-regression
model was performed. In this model, the significant factors from
the univariate analysis were removed one at a time, starting with
the factor that had the largest P-value, until all remaining factors
had a two-sided P-value of less than 0.10. Odds ratios and
P-values were reported for each factor alone and for the factors
found to be significant from the backward elimination. All statis-
tical tests were two-sided and the threshold for statistical signifi-
cance was set to P < 0.05.
Results
Study population
A total of 331 selected patients had resectable hilar
cholangiocarcinoma including 221 men and 110 women with a
median age of 61 years (range: 24–85). Hilar cholangiocarcinoma
was symptomatic in 223 (67%) patients and the most frequent
symptom was jaundice (75%). Fourteen (4%) had cholangitis at
presentation that was treated either with antibiotic therapy or
percutaneous/endoscopic biliary drainage. Two patients had hilar
cholangiocarcinoma develop on primary sclerosing cholangitis
and one patient had HVC-related cirrhosis. The baseline serum
bilirubin level was >50 μmol/l in 72%, > 100 μmol/l in 57% and
>200 μmol/l in 37% of patients. At the initial diagnosis, 64 (19%)
patients had suspected portal vein involvement on imaging.
Pre-operative biliary drainage was performed in 168 of the 248
(68%) jaundiced patients and 62 (19%) patients underwent
pre-operative PVE. In patients with available data (n = 93, 28%),
the median tumour diameter was 23 mm on pre-operative
imaging, ranging from 10 to 40 mm. Two hundred and seventy-
two (82%) patients were staged as Bismuth–Corlette type III–IV
(Table 1).
Surgery and early outcomes
The surgical procedures included 156 (47%) right hepatecto-
mies with resection of segment IVa, 169 (51%) left hepatecto-
mies and 7 (2%) anterior hepatectomies. All patients had a
lymphadenectomy including pericholedochal lymph nodes, and
lymph nodes around the common hepatic artery and the portal
vein. A lymphadenectomy included celiac lymph nodes in 25
(7.6%) patients and posterior pancreaticoduodenal lymph nodes
in 20 (6.0%). Five (1.5%) patients had resection of the aortocaval
paraaortic lymph nodes. The median number of sampled was 5,
ranging from 1 to 34 and the median lymph node ratio was 0.26
(range: 0.05–1). One hundred and twenty (36%) patients had
vascular clamping and 144 (43%) patients required an intra-
operative transfusion [median number of units of packed blood
cells: 3 (range: 1–16)]. Ninety (27%) patients underwent a com-
bined portal vein resection. The median operative time was
376 min (187–900) and the median blood loss was 760 ml (180–
3200). One hundred thirty-nine (42%) patients required an intra-
operative transfusion. The overall post-operative mortality rate
was 8.2% (n = 27) and 202 (61%) patients experienced complica-
tions after surgery [Dindo–Clavien I n = 42 (21%), II n = 61
(30%), III n = 79 (39%) and IV n = 20 (10%)]. Causes of death
were liver failure (n = 8), sepsis (n = 7), haemorrhage (n = 6),
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multiple organ failure (n = 3), massive pulmonary embolism (n =
1), acute cardiac failure (n = 1) and portal thrombosis (n = 1)].
The median length of hospitalization was 25 days (range: 9–92).
The median tumour size was 23 mm on pathology, ranging
from 8 to 40. The resection margins were R0 in 195 (59%) and R1
in 136 (41%) of the resected patients. Among the 331 patients
undergoing a lymphadenectomy, 136 (41%) had lymph node
involvement. Perineural invasion was confirmed in 94% of the 331
patients. Microscopic vascular invasion was confirmed in 84%.
Fifty-five per cent of the tumours were well differentiated, 36%
were moderately differentiated and 9% were poorly differentiated.
After resection, 73 (22%) patients received adjuvant therapy.
Chemotherapy (based on gemcitabine) was administered to 43
(13%) patients and radiation therapy was administered to 40
(12%) patients. Of these 73 patients, 10 received both chemo-
therapy and radiation therapy and 9 other patients had adjuvant
endobrachytherapy.
Overall survival
The 1-, 3- and 5-year overall survival rates in the 331 selected
patients were 85%, 64% and 53%, respectively. The 1-, 3- and
5-year disease-free survival rates were 81%, 49% and 32%, respec-
tively. The 1-, 3- and 5- overall survival rates in the 205 excluded
patients were 60%, 30% and 27%, respectively; these values were
significantly lower than those of the selected patients (P = 0.0001)
(Fig. 2).
Analysis of predictive factors for early death (within
12 months of resection) in selected patients
The numbers of patients who died during the follow-up periods
to 6 and 12 months were 24 and 37, respectively. Among these
patients, a tumour recurrence was confirmed on follow-up
imaging in 20 (55%) patients including the liver (n = 5), lungs
(n = 2), peritoneum (n = 7), bone (n = 5) and lymph node (n = 2).
For the 17 remaining patients, no data was specified in spite of
contacting the centres in question. As detailed in Table 2, symp-
tomatic tumour (P = 0.033), tumour size >30 mm (P = 0.004),
lymph node involvement (P = 0.038) and major complications
(P = 0.0001) were associated with early death (<12 months) in
univariate analysis. A tumour size >30 mm [OR 2.471 (95% CI
1.136–7.339), P = 0.001] and major post-operative complication
[OR 3.369 (95% CI 1.038–10.938), P = 0.004] were independently
associated with death < 12 months in a multivariate analysis.
When considered as continuous variables, age and tumour size
were significantly higher (63 versus 59 years, P = 0.03 and 31
versus 22 mm, P = 0.01, respectively) in patients who died at 12
months. In contrast, neither body mass index (24.2 versus 24.2 kg/
m2, P = 0.98) nor initial serum bilirubin level (178 versus
164 μmol/l, P = 0.31) were associated with early death.
Discussion
To our knowledge, this is the first large study with the purpose of
identifying hilar cholangiocarcinoma patients who were more
Table 1 Tumour staging (n = 331)
Tumour staging
n (%)
Staging on pre-operative imaging
Median tumour diameter (mm) 23 (10–40)a
Portal vein invasion 64 (19)
Hepatic artery invasion 16 (5)
Lobar atrophy 58 (17)
Lymph node enlargement 20 (6)
Bismuth–Corlette staging
I 12 (4)
II 47 (14)
III 242 (73)
IV 30 (9)
DeOliveira staging
Bile Duct (B)
B1 12 (4)
B2 47 (14)
B3-R 132 (40)
B3-L 110 (33)
B4 30 (9)
Tumour size (T)
T1 30 (9)
T2 126 (38)
T3 175 (53)
Tumour formb
Sclerosing 111 (43)
Mass 116 (45)
Mixed 21 (8)
Polypoid 10 (4)
Involvement of the portal vein (PV)
PV0 267 (81)
PV1 3 (1)
PV2 12 (3)
PV3 49 (15)
PV4 0 (0)
Involvement of the hepatic artery (HA)c
HA0 331 (100)
HA1 0 (0)
Lymph nodes (n)
N0 195 (59)
N1 136 (41)
Metastases (M)
M0 331 (100)
M1 0 (0)
aIn patients with available data (n = 238).
bThe data were not available in 73 (22%) patients.
cPatients requiring an arterial resection were excluded from the study.
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likely to die within 12 months after surgery. Unlike in a
recent Italian study including 440 patients with hilar
cholangiocarcinoma,16 we deliberately selected patients having
undergone a major liver resection of the right or left liver lobe
with segment I and bile duct; this criterion excluded nearly 35% of
the resected patients. We confirmed that patients with intra-
hepatic cholangiocarcinoma and hilar extension, patients treated
with neoadjuvant therapy, with minor or atypical resection, with
adjacent organ or arterial resection or without segment I resection
or without lymphadenectomy had a poorer overall survival than
the 331 selected patients. The present series also confirms our
previous prospective reports concerning the high rate of post-
operative mortality (8.2%) and morbidity (58%) after a major
hepatectomy5 and provided data on overall (85%, 64% and 53% at
1-, 3- and 5-years, respectively) and disease-free survival (81%,
49% and 32% at 1-, 3- and 5-years, respectively) in a population of
patients having received a theoretical optimal treatment.
To the best of our knowledge, this is the first time a series has
identified risk factors for early death (<12 months) after a
curative-intent resection. Even although tumour size has hardly
ever been noted in analyses of prognostic factors in hilar
cholangiocarcinoma (including the Japanese literature),17–22 we
found that a tumour size >30 mm on pathology was strongly
associated with death within 12 months of surgery in a multivari-
ate analysis. Interestingly, tumour size estimated on pre-operative
imaging corroborated tumour size evaluated on pathology in
the present study (23 versus 23 mm, P = 0.92). However, this
important result requires some caution because the measure-
ment of tumour size on pathology was not standardized in
different centres over a long study period. The present series
confirms the importance of the new grading system for hilar
cholangiocarcinoma proposed by DeOliveira et al.11 In the new
system, a tumor >30 mm in size is labelled as T3. The choice of a
30 mm cut-off for T3 was based on a growing body of data indi-
cating a better prognosis for smaller tumours;22,23 this includes
excellent outcomes after liver transplantation in the absence of
any extra-hepatic spread.24 Furthermore, this cut-off is particu-
larly relevant in patients considered for liver transplantation
because the original Mayo Clinic protocol and modified Mayo
protocols25,26 exclude all patients with a tumour size >30 mm.
Interestingly, our long-term results in resected patients are very
similar to overall results for cancers non developed on primary
sclerosing cholangitis after liver transplantation, as reported by
the group from Mayo Clinic (5-year survival 64%).26
Many previous studies have shown that a R0 resection with
adequate margins is an important prognostic factor for sur-
vival.17,27,28 In spite of an aggressive resection, patients are fre-
quently left with positive margins because it can be difficult to
predict the proximal boundary of the microscopic disease on the
basis of the pre-operative imaging data.29 As local resection
of the extrahepatic biliary system is associated with an incom-
plete tumour resection in more than two-thirds of patients, it is
Figure 2 Overall survival in the 331 selected patients and in the 205 excluded patients (Kaplan–Meier) (log-rank P = 0.0001)
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Table 2 Identification of variables associated with death within 12 months in the study population (uni- and multivariate)
Early death (<12 months)
Univariate analysis Multivariate analysis
OR (95%CI) P-value OR (95%CI) P-value
Patients characteristics
Male gender 1.15 (0.60–2.20) 0.666
Age >70 years 1.92 (0.99–3.72) 0.052 2.73 (0.76–9.80) 0.124
Jaundice 2.04 (0.81–5.13) 0.132
Cholangitis at presentation 2.13 (0.64–7.14) 0.219
Obese (BMI >30) 0.73 (0.09–6.17) 0.774
Symptomatic 2.23 (1.07–4.67) 0.033 1.29 (0.14–12.15) 0.823
Initial serum bilirubin level >200 μmol/l 1.42 (0.71–2.83) 0.312
Malnutrition 1.51 (0.42–5.41) 0.529
Co-morbidities
Diabetes mellitus 1.43 (0.41–5.00) 0.577
Hypertension 1.04 (0.45–2.41) 0.922
Ischaemic heart disease 1.83 (0.23–14.71) 0.568
COPD 4.13 (0.05–7.16) 0.517
Renal failure 2.59 (0.33–20.41) 0.364
Dyslipidemia 1.17 (0.25–5.46) 0.840
Alcohol abuse 2.00 (0.57–6.99) 0.276
Tobacco 1.62 (0.67–3.94) 0.288
Cancer 1.01 (0.28–3.66) 0.988
Surgical characteristics
Right-sided resection 0.84 (0.55–1.53) 0.565
Portal vein resection 1.70 (0.79–3.66) 0.176
Vascular clamping 0.60 (0.81–3.17) 0.176
Intra-operative transfusion 0.89 (0.48–1.65) 0.710
Tumour characteristics
Tumour size >30 mm 4.49 (1.64–12.33) 0.004 2.47 (1.14–7.34) 0.001
Bismuth III/IV 1.61 (0.59–4.43) 0.353
Microscopic vascular invasion 1.59 (0.03–29.81) 1.000
T stage 4.01 (1.13–9.27) 0.001
Lymph node involvement 3.02 (1.06–8.61) 0.038 1.87 (0.56–6.26) 0.311
Poor differentiation 3.12 (0.88–4.20) 0.106
R0 resection 0.64 (0.26–1.58) 0.329
Post-operative outcomes
Complication 4.51 (1.95–10.42) 0.0001
Major complication 5.22 (2.65–10.23) 0.0001 3.37 (1.04–10.94) 0.004
Liver-related complication 1.58 (0.81–3.08) 0.175
Pulmonary complication 1.09 (0.47–2.52) 0.831
Renal-related complication 0.97 (0.48–1.98) 0.935
Post-operative treatment
Adjuvant chemo 0.37 (0.11–1.28) 0.117
Adjuvant EBRT 0.75 (0.27–2.08) 0.576
OR, odds ratio; CI, confidence interval; BMI, body mass index; COPD, chronic obstructive pulmonary disease; EBRT, external beam radiation therapy.
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generally accepted that an additional, major liver resection of the
right or left liver lobe is essential. An additional caudate lobe
resection is recommended because direct infiltration along this
lobe’s bile ducts is reportedly responsible for a high rate of local
recurrence.30,31 Our rate of R1 resection was significantly higher in
our French series compared with the Italian’s after a liver resection
(41% versus 21%) and had been recently validated after a meticu-
lous pathological analysis.12 Although we would have expected
that tumours >30 mm predict a R1 resection and therefore poor
outcomes, multivariate analysis failed to find an association
between surgical margins and early deaths. However, a distinction
between early deaths owing to aggressive tumour behaviour and
early deaths that are the consequence of post-operative outcomes
is really difficult. The retrospective design may explain why only
59% of the patients who died within 12 months had proven recur-
rent disease. Indeed, we did not have complete data about recur-
rence in patients who died prematurely and recurrence is not
always the cause of deaths in this short-run follow-up. We do
believe that a significant proportion of these early deaths may in
part be related to post-operative outcomes.
We acknowledge that the present study had several limitations
which relate to the fact that cases were analysed retrospectively:
quality of control of surgical treatment and measurement of
tumour size on pathology are very difficult over a long study
period, as well as surgical procedure and peri-operative manage-
ment that were largely different from institute to institute.
However, a randomized controlled trial seems hardly feasible and
our study included a large number of patients treated with a major
liver resection for hilar cholangiocarcinoma provides useful clini-
cal information.
In conclusion, we showed for the first time that a sub-group of
patients with a large tumour (>30 mm) on pathology were more
likely to die within the 12 months after surgery.
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